Chemoembolization in Conjunction with Bevacizumab: Preliminary Results

Giammaria Fiorentini; Donatella Sarti; Camillo Aliberti; Riccardo Carandina; Luca Mulazzani; Alessandro Felicioli; Stefano Guadagni

doi:10.1016/j.jvir.2018.04.022

Chemoembolization in Conjunction with Bevacizumab: Preliminary Results

Giammaria Fiorentini, Donatella Sarti, Camillo Aliberti, Riccardo Carandina, Luca Mulazzani, Alessandro Felicioli, Stefano Guadagni

Istituto Oncologico Veneto

Research output: Contribution to journal › Article › peer-review

Abstract

Transarterial chemoembolization is an effective, minimally invasive therapy that is widely used for treatment of unresectable colorectal cancer liver metastases (CRC-LM). However, chemoembolization induces a hypoxic microenvironment, which increases neoangiogenesis and may promote early progression. For this reason, transarterial chemoembolization efficacy may be improved by combining it with an angiogenesis inhibitor, such as bevacizumab. This report shows that transarterial chemoembolization with irinotecan-loaded polyethylene glycol embolics and bevacizumab therapy was effective and well tolerated by 6 patients with CRC-LM, resulting in a disease control rate of 83% and an overall improvement in quality of life.

Original language	English
Pages (from-to)	1236-1239
Number of pages	4
Journal	Journal of Vascular and Interventional Radiology
Volume	29
Issue number	9
DOIs	https://doi.org/10.1016/j.jvir.2018.04.022
Publication status	Published - Sep 1 2018

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging
Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.jvir.2018.04.022

Cite this

@article{2cc5f87ef0a9480f8f317e779d9a0c03,

title = "Chemoembolization in Conjunction with Bevacizumab: Preliminary Results",

abstract = "Transarterial chemoembolization is an effective, minimally invasive therapy that is widely used for treatment of unresectable colorectal cancer liver metastases (CRC-LM). However, chemoembolization induces a hypoxic microenvironment, which increases neoangiogenesis and may promote early progression. For this reason, transarterial chemoembolization efficacy may be improved by combining it with an angiogenesis inhibitor, such as bevacizumab. This report shows that transarterial chemoembolization with irinotecan-loaded polyethylene glycol embolics and bevacizumab therapy was effective and well tolerated by 6 patients with CRC-LM, resulting in a disease control rate of 83% and an overall improvement in quality of life.",

author = "Giammaria Fiorentini and Donatella Sarti and Camillo Aliberti and Riccardo Carandina and Luca Mulazzani and Alessandro Felicioli and Stefano Guadagni",

year = "2018",

month = sep,

day = "1",

doi = "10.1016/j.jvir.2018.04.022",

language = "English",

volume = "29",

pages = "1236--1239",

journal = "Journal of Vascular and Interventional Radiology",

issn = "1051-0443",

publisher = "Elsevier Inc.",

number = "9",

}

TY - JOUR

T1 - Chemoembolization in Conjunction with Bevacizumab

T2 - Preliminary Results

AU - Fiorentini, Giammaria

AU - Sarti, Donatella

AU - Aliberti, Camillo

AU - Carandina, Riccardo

AU - Mulazzani, Luca

AU - Felicioli, Alessandro

AU - Guadagni, Stefano

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Transarterial chemoembolization is an effective, minimally invasive therapy that is widely used for treatment of unresectable colorectal cancer liver metastases (CRC-LM). However, chemoembolization induces a hypoxic microenvironment, which increases neoangiogenesis and may promote early progression. For this reason, transarterial chemoembolization efficacy may be improved by combining it with an angiogenesis inhibitor, such as bevacizumab. This report shows that transarterial chemoembolization with irinotecan-loaded polyethylene glycol embolics and bevacizumab therapy was effective and well tolerated by 6 patients with CRC-LM, resulting in a disease control rate of 83% and an overall improvement in quality of life.

AB - Transarterial chemoembolization is an effective, minimally invasive therapy that is widely used for treatment of unresectable colorectal cancer liver metastases (CRC-LM). However, chemoembolization induces a hypoxic microenvironment, which increases neoangiogenesis and may promote early progression. For this reason, transarterial chemoembolization efficacy may be improved by combining it with an angiogenesis inhibitor, such as bevacizumab. This report shows that transarterial chemoembolization with irinotecan-loaded polyethylene glycol embolics and bevacizumab therapy was effective and well tolerated by 6 patients with CRC-LM, resulting in a disease control rate of 83% and an overall improvement in quality of life.

UR - http://www.scopus.com/inward/record.url?scp=85051929426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051929426&partnerID=8YFLogxK

U2 - 10.1016/j.jvir.2018.04.022

DO - 10.1016/j.jvir.2018.04.022

M3 - Article

C2 - 30146190

AN - SCOPUS:85051929426

VL - 29

SP - 1236

EP - 1239

JO - Journal of Vascular and Interventional Radiology

JF - Journal of Vascular and Interventional Radiology

SN - 1051-0443

IS - 9

ER -

Chemoembolization in Conjunction with Bevacizumab: Preliminary Results

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this